What’s Happening with Propanc Shares This Monday?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: Benzinga
Public Offering Announcement: Propanc Biopharma, Inc. has priced a $4 million public offering of 1 million shares at $4.00 per share, which is expected to close today pending customary conditions.
Nasdaq Uplisting: The company received approval to uplist to the Nasdaq on August 14, with trading under the ticker symbol "PPCB" starting on August 15, after ceasing quotation on the OTC Markets Pink Tier.
Stock Performance: As of the latest data, Propanc shares have surged 136.55%, trading at $6.78.
Investment Options: Investors can purchase Propanc shares directly or through ETFs and mutual funds that include the stock, providing exposure to the healthcare sector.
Analyst Views on PPCB
About PPCB
Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
